Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma

Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China

NCT06315101 ·Status: COMPLETED

Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

NCT03289273 ·Status: COMPLETED

Optimization for Regorafenib in HCC

NCT04476329 ·Status: TERMINATED ·Phase: PHASE2

Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation

NCT04237740 ·Status: UNKNOWN ·Phase: PHASE3

Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma

NCT04310709 ·Status: COMPLETED ·Phase: PHASE2

Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma

NCT05444478 ·Status: RECRUITING ·Phase: NA

Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC

NCT06818097 ·Status: COMPLETED

Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC

NCT04241523 ·Status: UNKNOWN ·Phase: PHASE2

Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma

NCT06581315 ·Status: RECRUITING ·Phase: NA

Effects of Antiviral Therapy on Patients With HBV-related HCC

NCT05406089 ·Status: COMPLETED

Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

NCT04642547 ·Status: COMPLETED ·Phase: NA

Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma

NCT04183088 ·Status: UNKNOWN ·Phase: PHASE2

Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）

NCT04806243 ·Status: UNKNOWN ·Phase: PHASE2

Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC

NCT04615143 ·Status: RECRUITING ·Phase: PHASE2

Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment

NCT06923176 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.

NCT05162898 ·Status: NOT_YET_RECRUITING ·Phase: NA

The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma

NCT01972672 ·Status: COMPLETED ·Phase: PHASE2

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma

NCT05644379 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC

NCT05007587 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma

NCT04168944 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Efficacy and Safety of Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC: A Retrospective Real-world Study

NCT05638438 ·Status: UNKNOWN

Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma

NCT05609695 ·Status: UNKNOWN

Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1

NCT02129322 ·Status: WITHDRAWN ·Phase: PHASE2

Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma

NCT03801499 ·Status: WITHDRAWN ·Phase: PHASE2

A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC

NCT05773105 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2